A novel anti-TNF injection treatment for Dupuytren’s disease, developed at the University of Oxford in the UK, was the subject of a randomized, double-blind, placebo-controlled Phase 2b trial. Final efficacy data from the study has just been released. The study, “Anti-tumor necrosis factor therapy for early-stage Dupuytren’s disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled […]

Descartes-08, Cartesian Therapeutics’ investigational CAR T-cell therapy, appears generally safe and markedly lessened symptom severity in the first five patients with generalized myasthenia gravis (gMG) enrolled in a Phase 1b/2a clinical trial. “I am very encouraged by the interim analysis findings,” as the therapy “appears safe and well tolerated, and the extent of clinical improvement seen in our […]

Switching your career path will always feel like a daunting undertaking, and there’s no perfect time to do it. And to make matters worse, there will almost always be nay-sayers and moments of difficulty along the way to securing your new job. But that doesn’t mean you shouldn’t try. If you are interested in biopharma […]